Maxalt

Rizatriptan, the active ingredient in Maxalt, is a Triptan presented as an oral tablet for the acute treatment of migraine attacks in adults. It works by targeting serotonin receptors to relieve migraine symptoms and is prescribed for patients experiencing moderate to severe migraine episodes.

GNH USA supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from comprehensive regulatory support and consistent product availability across regions.

Rizatriptan is a triptan medication used for the acute management of migraine.

- Migraine attack: provides rapid relief of headache and associated symptoms. - Migraine with aura: alleviates aura‑related discomfort and speeds recovery. - Menstrual migraine: reduces the severity of attacks linked to the menstrual cycle.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Chest discomfort or tightness. - Tingling or numbness in the fingers or face. - Nausea or abdominal pain. - Dizziness or light‑headed feeling. - Fatigue or drowsiness. - Dry mouth.

Serious or Rare Side Effects: - Serotonin syndrome, especially when combined with other serotonergic agents. - Coronary vasospasm leading to chest pain or myocardial ischemia. - Severe allergic reactions such as anaphylaxis. - Persistent visual disturbances. - Sudden, unexplained weakness or paralysis. - Acute hypertension.

Before prescribing Rizatriptan, clinicians should evaluate individual risk factors and comorbidities.

- Cardiovascular assessment: avoid use in patients with uncontrolled hypertension or known coronary artery disease. - Concomitant triptans: do not combine with other triptan products to prevent additive vasoconstriction. - Ergot alkaloids: avoid simultaneous use due to increased risk of vasospasm. - Serotonergic agents: monitor closely when used with SSRIs, SNRIs, or MAO inhibitors. - Pregnancy and breastfeeding: consult a physician; safety data are limited. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Rizatriptan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Other triptans: additive vasoconstrictive effect. - Ergot alkaloids (e.g., ergotamine): heightened vasospasm risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels.

Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, or other serotonergic antidepressants: monitor for serotonin syndrome. - Antihypertensive agents: possible additive blood pressure effects. - Certain anti‑emetics (e.g., metoclopramide): may alter absorption.